Read More

Bristol Myers Squibb’s Stocks Falls on Q2 Miss, FY23 Forecast Cut As Two Of Its Top Drugs Face Generic Competition

Bristol Myers Squibb & Co (NYSE: BMY) said that its Q2 revenues of $11.23 billion declined 6% Y/Y, or 5% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line products and our new product portfolio.

BMY